– Weekly subcutaneous eloralintide (an amylin receptor agonist) produced dose‑dependent mean weight loss of 9.4% to 20.9% at 48 weeks versus 0.4% with placebo in a randomized phase 2 trial (n=263).
– Dose‑escalation strategies (eg, 6→9 mg) were associated with large weight loss (≈19.9%) and lower discontinuation due to adverse effects compared with forced higher‑dose starts.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
